Migraine: latest news - GoINPHARMA
Saturday, 15 December 2018 - 21:47

Migraine

New therapies preventing migraine episodes to be launched

US-based drugmaker Eli Lilly & Co. on Friday announced that EMA has recommended the marketing approval in Europe for its monoclonal antibody Emgality (galcanezumab). Emgality has already been granted conditional approval in the US by FDA. It is part of…

FDA approves Teva’s Ajovy (migraine)

Teva Pharmaceuticals yesterday announced that FDA has approved Ajovy (fremanezumab) for the prevention of migraine. Ajovy is an anti-peptide monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), designed for episodic migraine and chronic migraine prevention in adults. Fremanezumab is…

FDA accepts BLA for Teva’s fremanezumab

Teva Pharmaceutical today has announced that FDA has accepted its BLA (Biologics License Application) for fremanezumab, an anti-CGRP monoclonal antibody for the preventive treatment of migraine. Additionally, the Administration has granted Fast Track Designation to the product for the prevention…

Amgen announces Phase III results from migraine therapy

Amgen yesterday reported that The New England Journal of Medicine had published results from the Phase III STRIVE clinical trial, assessing the investigational drug Aimovig (erenumab) vs placebo for the prevention of chronic migraine. Aimovig is a monoclonal antibody that…

Excellent Phase III results for Teva’s chronic migraine therapy

The New England Journal of Medicine yesterday reported in a relevant article the results from the Phase III HALO trial, designed to assess the investigational drug fremanezumab, developed by Teva, on 1130 patients. The medicine, believed to be the most…

Migraine, Teva submits BLA to FDA for fremanezumab

Teva Pharmaceuticals Industries has announced it has submitted a BLA (Biologics License Application) to FDA for fremanezumab, an anti-CGRP monoclonal antibody for the prevention of migraine. The application is based on results from the HALO clinical trial program, which enrolled…

EMA accepts application for Novartis/Amgen’s migraine treatment

Novartis announced that EMA accepted its MAA (Marketing Authorization Application) for AMG 334 (erenumab) for the prevention of migraine. The drug is an anti-CGRP monoclonal antibody which binds selectively to the CGRP receptor, believed to play a critical role in…

Positive times for Teva

Teva Pharmaceuticals is having positive times. The company reported positive Phase III results from Fremanezumab as an investigational therapy for acute migraines. The data showed that once-monthly Fremanezumab clearly helps ease the disease. Teva expects it will submit an approval…

AstraZeneca sells Zomig to Grünenthal for $302m

UK-based pharmaceutical group AstraZeneca sold commercialization rights to Zomig, a treatment of migraines and cluster headaches to Germany’s Grünenthal for $302m. Specifically, under the agreement, Zomig will market the product in all markets outside Japan, including the US, where Zomig…

Episodic migraine, positive results for Amgen/Novartis’ AMG 334

Novartis today announced positive results from ARISE, a Phase-III trial aimed at evaluating the efficacy and safety of monthly AMG 334 (erenumab) 70mg in episodic migraine prevention in 577 patients. The study met the primary endpoint, demonstrating a statistically significant…

Chronic migraine, Phase III data for Amgen/Novartis’ antibody now presented

Novartis today announced complete Phase II results showing the fully human monoclonal antibody named AMG 334 (erenumab) produced a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. Among trial participants, a significantly larger…